Certara (NASDAQ:CERT) Earns “Market Perform” Rating from William Blair

Certara (NASDAQ:CERT)‘s stock had its “market perform” rating reaffirmed by investment analysts at William Blair in a research note issued on Thursday,RTT News reports.

A number of other research firms also recently weighed in on CERT. TD Cowen started coverage on shares of Certara in a research note on Thursday. They issued a “buy” rating and a $16.00 price target on the stock. Stephens reissued an “overweight” rating and set a $17.00 price objective on shares of Certara in a report on Thursday. Barclays lowered their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, November 7th. Finally, Robert W. Baird cut their price target on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 5th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $15.79.

Certara Stock Down 3.4 %

Shares of CERT opened at $11.98 on Thursday. The firm has a 50 day simple moving average of $12.45 and a two-hundred day simple moving average of $11.64. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. Certara has a one year low of $9.41 and a one year high of $19.87. The company has a market cap of $1.93 billion, a P/E ratio of -59.90, a P/E/G ratio of 9.29 and a beta of 1.57.

Institutional Investors Weigh In On Certara

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Mackenzie Financial Corp bought a new stake in Certara in the fourth quarter valued at approximately $17,852,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Certara by 16.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 263,574 shares of the company’s stock worth $2,807,000 after purchasing an additional 37,870 shares during the period. Voloridge Investment Management LLC boosted its stake in shares of Certara by 269.3% in the 4th quarter. Voloridge Investment Management LLC now owns 275,633 shares of the company’s stock valued at $2,935,000 after purchasing an additional 201,003 shares during the last quarter. Squarepoint Ops LLC boosted its stake in shares of Certara by 62.7% in the 4th quarter. Squarepoint Ops LLC now owns 94,433 shares of the company’s stock valued at $1,006,000 after purchasing an additional 36,386 shares during the last quarter. Finally, Two Sigma Advisers LP increased its position in shares of Certara by 35.7% during the fourth quarter. Two Sigma Advisers LP now owns 87,500 shares of the company’s stock worth $932,000 after buying an additional 23,000 shares during the period. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.